Phase 1 Myasthenia Gravis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Group 1 – Relapsing Multiple Sclerosis (MS):
- You have a relapsing form of MS with a disability level score between 3.0 and 5.5 on a standard MS scale (confirm with trial site)
- Your MS has gotten worse within the last 12 months even while taking a strong MS medication for at least 6 months
Group 2 – Progressive MS:
- You have a progressive form of MS with a disability level score between 3.0 and 6.0 on a standard MS scale (confirm with trial site)
- You have been diagnosed with either a primary progressive MS that hasn't responded to treatment, or an inactive secondary progressive MS
Group 3 – Myasthenia Gravis (a muscle weakness condition):
- Your myasthenia gravis has been classified at a moderate to severe level at the time of screening (confirm with trial site)
- Blood tests (past or current) show specific proteins that are linked to myasthenia gravis
- Your condition has remained active despite trying at least 2 different immune-suppressing treatments, including steroids or other medicines
- If it was medically recommended, you have already had surgery to remove your thymus gland
Who may not be able to join:
- (Groups 1 & 2) You are unable to complete a standard hand coordination test (picking up pegs) with at least one hand within 4 minutes
- You are unable to walk 25 feet within 150 seconds on a standard walking test
- You have another condition affecting your nerves or muscles — such as stroke, myositis, or certain other nerve diseases — that could affect the results
- There are additional criteria not listed here that the trial team will check (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs); Number of participants with adverse events of special interest (AESIs); Number of participants with laboratory test result abnormalities; Number of participants with imaging abnormalities; Number of participants with dose-limiting toxicities (DLTs); Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.